Opus Genetics IRD
NASDAQ IRD
$4.68 +0.09 (+1.85%)
As of: Sep 4, 2026 · 3:11 PM EDT

Opus Genetics (IRD) Non Operating Interest Expenses (2020 - 2026)

Analysis

Opus Genetics (IRD) Non Operating Interest Expenses (2020 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.58 Bn 130.73 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.33 Bn 77.33 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.43 Bn 58.24 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.84 Bn 52.70 Bn 52.00 Mn -
5 Revolution Medicines 44.01 Bn 44.01 Bn - 23.78 Mn
6 BeOne Medicines 39.93 Bn 34.83 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.47 Bn 32.16 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.39 Bn 27.56 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Opus Genetics 447.34 Mn 358.53 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 69,000.00
Dec 31, 2025 61,000.00
Sep 30, 2025 68,000.00
Jun 30, 2022 4,000.00
Mar 31, 2022 5,000.00
Dec 31, 2021 2,000.00
Dec 31, 2020 5.43 Mn
Sep 30, 2020 179,000.00
Jun 30, 2020 689,000.00
Mar 31, 2020 554,000.00